• Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Contact
  • Investor Login
  • Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Investor Login

Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease

CHICAGO, Dec. 8, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to… Read More

Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery

Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery   Signs Definitive Agreement to Acquire Standard Bariatrics   WAYNE,… Read More

They’re Back – Will We See the M&A Boon? Hatteras White Paper on Biotech M&A

By: Clay Thorp, General Partner, Hatteras Venture Partners   Michael Yee of Jefferies is one of the best analysts in biotech, and he knows his… Read More

Qvella FAST System and FAST-PBC Prep Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use

With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current… Read More

Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform

Company also secures $9.5 million in Series A funding to expand its resources to meet rapidly growing customer demand   PALO ALTO, Calif.–(BUSINESS… Read More

Aledade Acquires Advance Care Planning Company Iris Healthcare as Part of New Health Services Arm

Acquisition Enables Company to Provide More High-Value, Patient-Centered Services Through Its Network of More Than 1,000 Independent Primary Care Practices and Health Centers   Bethesda, Md. Read More

VIGIL NEUROSCIENCE ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia… Read More

Tune Therapeutics Debuts with $40 Million to Fine-Tune the Human Genome

A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with… Read More

Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 Million Investment in Elligo

Proceeds Used to Acquire ClinEdge and Invest Further in Technology & Data Platform SAN FRANCISCO–(BUSINESS WIRE)– Morgan Stanley Expansion Capital and Ally Bridge Group,… Read More

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

First Indication for Lead TREM2 Agonist Program Announced as Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Financing Led by Vida Ventures; Stefan… Read More

  • Team
  • Approach
  • Portfolio
  • News
  • Blog
  • Contact
  • Investor Login